TapImmune Inc. (OTCMKTS:TPIV) was a notable mover during Friday’s trading session rallying by 2.5% on above average volumes which were 1.2 times the average turnover. The stock has witnessed strong buying interest emerge after it took at support at levels of $0.554.TapImmune currently trades above all daily moving averages, which is a bullish sign. The MACD oscillator continues to trend with a bullish bias indicative of strong buy side momentum. The RSI indicator shows no signs of an intermediate reversal, which is being seen as a huge positive. Traders believe the stock could trend lower towards levels of $0.780.


TapImmune Inc. (OTCMKTS:TPIV) and Minnesota-based Mayo Clinic have entered an exclusive licensing deal for the breast cancer vaccine development. The license was not possible unless the Phase 1 laboratory trial on breast cancer patients and under the agreement, Mayo Clinic will conduct this clinical trial on those patients who have the Her2/neu breast cancer. The lead researcher for this trial would be Dr Keith Knutson.

Even as many other companies are currently undertaking trials for the vaccine for treating Her2/neu but the limited access and ability to heal the cancer sufferers poses as a grave problem for most of the vaccines being developed to fight the ailment. According to TapImmune Inc, the technology that they are using is aimed at covering 90% of the patients with the Her2/neu breast cancer and gives longer results. This will help providing a better treatment to patients suffering from the disease.

Cancer Vaccine Portfolio

TapImmune Executive Chairman Dr Glynn Wilson informed that the license procurement for the Mayo Clinic technology would enhance the cancer vaccine profile and laboratory research pathways of the company. As the vaccine that will be developed could cater to more people, it could be a life-saver from many people.

The company has an option of getting a license for fighting ovarian cancer that is in the last stage of the Phase 1 clinical trial. According to Wilson, this was an exciting development as there were immense opportunities that this drug could help the company to explore.

Vaccine For Small Pox

Meanwhile, TapImmune Inc. and Mayo Clinic have also entered a deal for manufacturing the smallpox vaccine through a Sponsored Research & and Licensing deal. Dr Gregory Poland, MD, Mayo Clinic’s Vaccine Research Laboratory will study the novel peptide antigens and the TAP technology of TapImmune to find the relation between them. The license can be applied once the study is completed as per the agreed terms of both the parties. Dr Poland is going to try and find a vaccine that could help fight small pox with the live virus technology that is used currently to fight small pox. With the current deal, the company aims at becoming a pioneer in providing an effective vaccine to the small pox patients and help stop recurrence of the ailment.